|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.08.26 - 22:06
|
Evolus Reports Strong Second Quarter 2026 Financial Results; Delivers Third Consecutive Quarter of Positive Adjusted EBITDA and Raises Full-Year 2026 Financial Outlook (Business Wire)
|
|
|
Global Net Revenue of $84.1 Million for the Second Quarter of 2026, an Increase of 21% Over the Prior Year, Reflecting Increasing Market Share Gains Across U.S. and International Markets
GAAP Operating Loss of $4.5 Million and Positive Adjusted EBITDA of $4.7 Million for the Second Quarter of 2026, Representing the Third Consecutive Quarter of Positive Adjusted EBITDA, a $12.6 Million Year-Over-Year Improvement
Raises Full-Year 2026 Net Revenue Guidance to Between $330 Million and $337 Million, Raises Adjusted Gross Profit Margin Guidance to Between 67.0% and 67.5%, Narrows Non-GAAP Operating Expense Guidance to Between $212 Million and $216 Million, While Reaffirming Low- to Mid-Single Digit Adjusted EBITDA Margin Outlook
Expansion of the Company's Global Injectable Portfolio Through the Addition of Profhilo®, the Third Vertical in the U.S. Injectable Portfolio, With Estimated Peak Annual Revenue Exceeding $100 Million and Anticipated U.S. Commercialization in 2030, and the Expansion of the Estyme® Fr...
|
|
|
22.07.26 - 14:36
|
Evolus to Report Second Quarter Financial Results on August 5, 2026 (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the U.S. financial markets close.Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13761330. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.About Evolus, Inc.Evolus (NASDAQ: EOLS) is a gl...
|
|
|
10.07.26 - 22:06
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant during April 2026 to July 2026 of an aggregate of 115,000 restricted stock units (RSUs) of the company's common stock to 38 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with grant dates and vesting commencement dates ranging from April 7, 2026 through July 8, 2026, as inducements material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4).The RSUs vest 25% on each annual anniversary of the vesting commencement date. The awards are subject to the terms and conditions of the 2023 Inducement Incentive Plan and the terms and conditions of the RSU agreement covering the grant, including requirements to remain continuou...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
04.05.26 - 22:06
|
Evolus Reports First Quarter 2026 Financial Results; Company Delivers Second Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year Outlook (Business Wire)
|
|
|
Global Net Revenue of $73.1 Million for the First Quarter of 2026, Up 7% Over the Prior Year and Against the Highest Growth Quarter of 2025
GAAP Operating Loss of $6.8 Million and Adjusted EBITDA of $0.6 Million for the First Quarter of 2026, Representing the Second Consecutive Quarter of Positive Adjusted EBITDA and a Significant Improvement from a Loss of $5.5 Million in the Prior Year Period
Reaffirms Full-Year 2026 Net Revenue Guidance of $327 Million to $337 Million and Non-GAAP Operating Expenses of $210 Million to $216 Million; Company Continues to Expect to Achieve a Low- to Mid-Single Digit Adjusted EBITDA Margin in 2026
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its financial results for the first quarter ended March 31, 2026.
“We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability1 in what is seasonal...
|
|
|
14.04.26 - 14:36
|
Evolus to Report First Quarter Financial Results on May 4, 2026 (Business Wire)
|
|
|
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2026 financial results on Monday, May 4, 2026, after the U.S. financial markets close.
Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here.
Following the completion of the call, a telephonic replay can be accessed by dialing (877) 660-6853 (U.S.) or (201) 612-7415 (international) and using conference number 13759697. An archived webcast can also be accessed on the Investor Relations page of the Evolus website at www.evolus.com.
About Evolus, Inc.
Evolus (NASDAQ: EOLS) is a glob...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
